Key Takeaways
- •Eli Lilly’s shares have risen 9.27% over the past month, propelled by a strong first-quarter earnings report.
- •The 24/7 Wall St.
- •Eli Lilly released its first-quarter 2026 earnings on April 30, delivering revenue of $19.799 billion.
Eli Lilly Stock Targets $1,164.85 After Q1 Surge
Eli Lilly’s shares have risen 9.27% over the past month, propelled by a strong first-quarter earnings report. The rebound follows a decline earlier in 2026, driven by concerns over pricing pressures and market saturation in the obesity and diabetes treatment space. Key products Mounjaro (tirzepatide) and Zepbound (tirzepatide for weight management) continue to anchor growth, but the company’s pipeline also shows promise with an oral GLP-1 pill and a novel triple agonist.
The 24/7 Wall St. price target of $1,164.85 represents a 14.68% potential increase from the current price of $1,015.75. Analysts assign a buy rating with 90% confidence, citing sustained earnings growth, sector stability, and a robust pipeline that could reshape metabolic disorder therapy.
| Metric | Value |
|---|---|
| Current Price | $1,015.75 |
| 24/7 Wall St. Price Target | $1,164.85 |
| Recommendation | Buy |
| Confidence Level | 90% |
Q1 2026 Earnings Beat Expectations
Eli Lilly released its first-quarter 2026 earnings on April 30, delivering revenue of $19.799 billion. This figure exceeded consensus estimates by 11.25% and represented a 55.55% surge compared to the prior year’s quarter. Non-GAAP earnings per share reached $8.55, topping the $6.79 analyst consensus by a wide margin.
Mounjaro alone generated $8.662 billion in global sales, a 125% year-over-year increase, while Zepbound contributed $4.16 billion. Management updated full-year 2026 guidance to between $82 billion and $85 billion in revenue, with Non-GAAP EPS expected in the range of $35.50 to $37.00. Despite the quarterly strength, shares remain 5.33% lower year-to-date and trade approximately 7% below their 52-week high of $1,132.06.
Bull Case Highlights Pipeline Advances
Beyond the blockbuster tirzepatide franchise, Eli Lilly’s pipeline features two notable candidates that could extend its dominance in the incretin class of drugs.
Foundayo, also known as orforglipron, is an oral GLP-1 receptor agonist that has been approved in certain markets. Unlike many oral GLP-1 compounds, it has no restrictions on food or water intake, offering a convenient alternative to injectable therapies. A trial published in The Lancet demonstrated that orforglipron outperformed oral semaglutide (the active ingredient in Rybelsus) in glycemic control and weight reduction. This is significant because oral semaglutide requires strict dosing conditions with water and no food for at least 30 minutes. Orforglipron’s profile could expand access to patients who are needle-averse or face barriers to injectable treatments.
Retatrutide, a once-weekly triple agonist targeting the GIP, GLP-1, and glucagon receptors, has met its Phase 3 endpoints in type 2 diabetes. The triple mechanism is designed to produce greater weight loss and glycemic improvements than dual agonists like tirzepatide. If approved, retatrutide could serve as a next-generation therapy for metabolic diseases, potentially broadening Eli Lilly’s market and offering a competitive edge over rivals like Novo Nordisk.
Mounjaro also gained inclusion in China’s National Reimbursement Drug List (NRDL), a government program that expands coverage and access for domestic patients. This contributed to an 81% increase in rest-of-world revenue for the drug, underscoring the importance of global market expansion for the incretin class.
Analyst consensus targets average $1,209.14, with 24 buy ratings currently assigned to the stock. The bull scenario projects a 12-month price of $1,227.11, implying a total return of 20.81% including dividends.
Key Risks and Bear Considerations
Despite the strong performance, investors face several notable risks. Pricing pressures reduced realized prices by 13% in Q1, driven by lower cash prices for Zepbound in the United States and reimbursement effects tied to China’s NRDL inclusion. The company recorded $584 million in IPR&D (in-process research and development) charges, along with $279 million in litigation and restructuring costs. Incremental pricing declines could erode margins if volume growth slows.
Revenue concentration is another concern: incretin products now dominate Eli Lilly’s top line, leaving the company vulnerable to regulatory shifts, competition, or safety setbacks in this drug class. Prediction markets estimate a 19% chance of federal government involvement in pricing or coverage, which could introduce price controls or mandatory discounts.
On a more positive note, IPR&D charges dropped significantly from $1.6 billion in the prior year, and strong volume growth of 65% helped offset the price reductions. The bear case target of $982.92 would represent a 3.23% decline from current levels, suggesting limited downside if the company maintains execution.
Forward Outlook Remains Positive
The $1,164.85 price target and buy rating reflect 90% confidence in Lilly’s earnings trajectory and pipeline progress. Foundayo’s oral formulation could unlock a broader patient population, especially those who avoid injections. Its success hinges on a smooth market launch and favorable reimbursement. Mounjaro’s global expansion, particularly in China and other emerging markets, adds further upside.
Projections assume continued growth of GLP-1 drugs and successful pipeline execution, with retatrutide approval representing a potential catalyst in the next 12 to 18 months. Longer-term risks include biosimilar competition that could erode pricing power. For now, the rewards are assessed as outweighing the risks, given the company’s established market position and robust clinical development.
Frequently Asked Questions
Q: What is the price target for Eli Lilly stock and what does it imply?
A: The 24/7 Wall St. price target is $1,164.85, which is about 14.68% above the current price of $1,015.75. Analysts have a buy rating with 90% confidence based on expected earnings growth and the stability of the obesity and diabetes drug market.
Q: What drove the strong Q1 2026 earnings for Eli Lilly?
A: Revenue reached $19.799 billion, beating estimates by 11.25%, with non-GAAP EPS of $8.55 versus the $6.79 consensus. Key drivers were Mounjaro sales of $8.662 billion (up 125%) and Zepbound sales of $4.16 billion. The company also updated its full-year guidance to $82-$85 billion in revenue.
Q: What are Foundayo and retatrutide, and why are they important?
A: Foundayo (orforglipron) is an oral GLP-1 pill with no food or water restrictions. In a Lancet trial it outperformed oral semaglutide in blood sugar control and weight loss. Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors, and it met Phase 3 goals in type 2 diabetes. Both could expand Eli Lilly’s market beyond injectable therapies.
Q: What are the main risks facing Eli Lilly’s stock?
A: Pricing pressures reduced realized prices by 13% in Q1, partly due to lower Zepbound cash prices and China reimbursement effects. The company also faced $584 million in IPR&D charges and $279 million in litigation and restructuring costs. Revenue concentration in incretin drugs and a 19% chance of federal pricing involvement are additional concerns.